JP2023508491A5 - - Google Patents

Info

Publication number
JP2023508491A5
JP2023508491A5 JP2022539641A JP2022539641A JP2023508491A5 JP 2023508491 A5 JP2023508491 A5 JP 2023508491A5 JP 2022539641 A JP2022539641 A JP 2022539641A JP 2022539641 A JP2022539641 A JP 2022539641A JP 2023508491 A5 JP2023508491 A5 JP 2023508491A5
Authority
JP
Japan
Application number
JP2022539641A
Other languages
Japanese (ja)
Other versions
JPWO2021133866A5 (https=
JP2023508491A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/066762 external-priority patent/WO2021133866A1/en
Publication of JP2023508491A publication Critical patent/JP2023508491A/ja
Publication of JPWO2021133866A5 publication Critical patent/JPWO2021133866A5/ja
Publication of JP2023508491A5 publication Critical patent/JP2023508491A5/ja
Pending legal-status Critical Current

Links

JP2022539641A 2019-12-26 2020-12-23 骨髄線維症の治療のための化合物 Pending JP2023508491A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953654P 2019-12-26 2019-12-26
US62/953,654 2019-12-26
PCT/US2020/066762 WO2021133866A1 (en) 2019-12-26 2020-12-23 Compounds for the treatment of myelofibrosis

Publications (3)

Publication Number Publication Date
JP2023508491A JP2023508491A (ja) 2023-03-02
JPWO2021133866A5 JPWO2021133866A5 (https=) 2023-12-26
JP2023508491A5 true JP2023508491A5 (https=) 2023-12-26

Family

ID=74186982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539641A Pending JP2023508491A (ja) 2019-12-26 2020-12-23 骨髄線維症の治療のための化合物

Country Status (11)

Country Link
US (1) US20230062278A1 (https=)
EP (1) EP4081213A1 (https=)
JP (1) JP2023508491A (https=)
KR (1) KR20230005808A (https=)
CN (1) CN115697323A (https=)
AU (1) AU2020415440A1 (https=)
BR (1) BR112022012819A2 (https=)
CA (1) CA3166251A1 (https=)
IL (1) IL294369A (https=)
MX (1) MX2022008046A (https=)
WO (1) WO2021133866A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) * 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
CN113384546A (zh) * 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
CN106349224A (zh) * 2016-08-03 2017-01-25 山东大学 一种含有4‑氨基‑(1h)‑吡唑结构的jak激酶抑制剂及其制备方法和应用
WO2019222483A1 (en) * 2018-05-17 2019-11-21 Board Of Regents, The University Of Texas System Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
CN112351819B (zh) * 2018-06-05 2023-11-10 开动疗法公司 治疗恶性淋巴增生性疾病的方法

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021013929A2 (https=)
BR102021012230A2 (https=)
BR102021012003A2 (https=)
BR102021012107A2 (https=)